最新医学別冊　新しい診断と治療のABC30/代謝3　糖尿病合併症

出版社： 最新医学社
発行日： 2005-07-25
分野： 臨床医学：一般  >  雑誌
雑誌名：
特集： 糖尿病合併症
電子書籍版： 2005-07-25
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

5,500 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

4,400 円(税込)

購入する

目次

  • 最新医学別冊　新しい診断と治療のABC30/代謝3　糖尿病合併症

    ―目次―

    特集　糖尿病合併症

    第1章　糖尿病合併症の疫学
    　糖尿病合併症の疫学

    第2章　糖尿病合併症の病因・病態生理
    　糖尿病細小血管症の成因
    　糖尿病大血管症の成因
    　メタボリックシンドロームと糖尿病大血管症
    　脂質代謝異常と糖尿病大血管症
    　高血圧と糖尿病大血管合併症

    第3章　糖尿病合併症の診断・管理・治療
    　糖尿病網膜症
    　糖尿病腎症
    　糖尿病神経障害
    　糖尿病大血管症

    第4章　糖尿病合併症のガイドライン
    　糖尿病細小血管症の治療とEBMとガイドライン
    　糖尿病大血管症のための糖尿病診療ガイドライン

    第5章　糖尿病合併症のトピックス
    　食後高血糖と糖尿病合併症
    　酸化ストレスと糖尿病合併症
    　アディポネクチンと糖尿病合併症
    　糖尿病合併症の遺伝素因
    　糖尿病合併症の遺伝子治療

    座談会：糖尿病合併症の発症・進展阻止に向けた管理の進め方

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 糖尿病合併症の疫学

P.17 掲載の参考文献
1) Klein R, et al:Diabetic eye disease. Lancet 350:197-204, 1997.
PubMed
2) Yokoyama H, et al:Existence of Early-On-set NIDDM Japanese Demonstrating Severe Diabetic Complications. Diabetes Care 20 (5):844-847, 1997.
 
3) Hovind P, et al:Decreasing Incidence of Severe Diabetic Microangiopathy in Type 1 Diabetes. Diabetes Care 26 (4):1258-1264, 2003.
PubMed
4) The Diabetes Control and Complications Trial Research Group:The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (14):977-986, 1993.
 
5) Shichiri M, et al:Long-Term Results of the Kumamoto Study on Optimal Diabetes control in Type 2 Diabetic Patients. Diabetes Care 23 (Suppl2):B21-29, 2000.
 
6) 日本透析医学会統計調査委員会 同小委員会:わが国の慢性透析療法の現状 (2003年12月31日現在). 日透析医会誌 38:1-16, 2005.
 
7) Krolewski A S, et al:The Changing Natural History of Nephropathy in Type 1 Diabetes. Am J Med 78:785-794, 1985.
PubMed
8) Ritz E, et al:Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 341 (15):1127-1133, 1999.
PubMed
9) 富野康日己, 他:糖尿病性腎症の疫学. 腎と透析 2001 臨時増刊号 42-45, 2001.
 
10) Quinn M, et al:Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia 39:940-945, 1996.
PubMed
11) Nishimura R, et al:Incidence of ESRD and Survival After Renal Replacement Therapy in Patients With Type 1 Diabetes:A Report From the Allegheny County Registry. Am J Kidney Dis 42 (1):117-124, 2003.
PubMed
12) Yokoyama H, et al:Higher incidence of diabetic nephropathy in type 2 than type 1 diabetes in early-onset diabetes in Japan. Kidney International 58 (1):302-311, 2000.
PubMed
13) UKPDS Group:Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2diabetes (UKPDS 33). Lancet 352:837-853, 1998.
 
14) 馬場園哲也, 他:糖尿病性腎症透析患者の生命予後に影響する病態. 腎と透析 2001 臨時増刊号:563-567, 2001.
 
15) 田嶼尚子, 他:首都圏糖尿病患者における糖尿病性神経障害の実態調査. 糖尿病 46 (4):301-309, 2003.
 
16) Fedele D, et al:A Multicenter Study on the Prevalence of Diabetic Neuropathy in Italy. Diabetes Care 20 (5):836-843, 1997.
 
17) Dyck PJ, et al:The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort. Neurology 43:817-824, 1993.
 
18) Lozeron P, et al:Symptomatic diabetic and non-diabetic neuropathies in a series of 100 diabetic patients. J Neurol 249:569-575, 2002.
 
19) Fujishima M, et al:Diabetes and Cardiovascular Disease in Prospective Population Survey in Japan. Diabetes 45 (suppl 3):S14-S16, 1996.
 
20) DECODE Study Group:Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of Europian epidemiological data. BMJ 317:371-375, 1998.
 
21) DECODA Study Group:Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia 47:385-394, 2004.
 
22) Tominaga M, et al:Impaired Glucose Tolerance Is a Risk Factor for Cardiovascular Disease, but Not Impaired Fasting Glucose. Diabetes Care 22 (6):920-924, 1999.
 
23) 山田信博:metabolic syndrome. 日医新報 4213:19-29, 2005.
 
24) Hanefeld M, et al:A carbose reduces the risk for myocardial infarction in type 2 diabetic patients:meta-analysis of seven long-term studies. Eur Heart J 25 (1):10-16, 2004.
 
25) Haffner S, et al:Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339 (4):229-234, 1998.
PubMed

第2章 糖尿病合併症の病因・病態生理

P.27 掲載の参考文献
1) The Diabetes Control and Complication Trial Research Group:The effect of intenslve treatment of diabetes on the development and progression of long-term complications in insurin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993.
 
2) U. K. Prospective Diabetes study (UKPDS) Group:Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet 352:837-853, 1998.
 
3) Ohkubo Y, et al:Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus:a randomized prospective 6 year study. Diabetes Res Clin Pract 28:103-117, 1995.
PubMed
4) Maillard ML-C:Comptesrendus des travaux du Laboratoire Carlesberg:66-67, 1912.
 
5) Miura J, et al:Serum levels of non-carboxymethyllysine advanced glycation endoproducts are correlated to severity of microvascular complications in patients with type 1 diabetes. J Diab Comp 17:16-21, 2003.
 
6) Koschinsky T, et al:Orally absorbed reactive glycation products (glycotoxins):an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA 94:6474-6479, 1997.
PubMed
7) Neeper M, et al:Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267:14998-15004, 1992.
PubMed
8) Yonekura H, et al:Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 370:1097-1109, 2003.
PubMed
9) Schmidt A M, et al:Activation of receptor for advanced glycation endproducts:a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 84:489-497, 1999.
PubMed
10) Tanaka N, et al:The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 275:25781-25790, 2000.
 
11) Miura J, et al:AGE downregulation on monocyte RAGE expression and its association with diabetic complications in Type 1 diabetes. J Diab Comp 18:53-59, 2004.
 
12) Yamagishi S, et al:Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothehal growth factor. J Biol Chem 272:8723-8730, 1997.
 
13) Tsujii H, et al:Ribozyme targeting of receptor for advanced glycation end products in mouse mesangial cells. Biochem Biophys Res Commun 245:583-588, 1998.
 
14) Yamamoto Y, et al:Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 108:261-268, 2001.
PubMed
15) Yonekura H, et al:Role of the receptor for advanced glycation endproducts in diabetes-induced vascular injury. JPharmacol Sci 97:305-311, 2005.
 
16) 堀田饒:糖尿病における最小血管症の分子生物学. 糖尿病学 1997 (小阪樹徳, 他編) p190-224. 診断と治療社, 東京, 1997.
 
17) Richard S, et al:Tissue-specific effects of aldose reductase inhibition on fluorescence and cross-linking of extracellular matrix in chronic galactosemia. Relationchip to pentosidine cross-links. Diabetes 40:1049-1056, 1991.
 
18) Koya D, et al:Protein kinase C activation and the development of diabetic complications. Diabetes 47:859-866, 1998.
PubMed
19) Ishii H, et al:Amelioration of vascular dysfunctions in diabetic rats by an oral PKC? inhibitor. Science 272:728-731, 1996.
PubMed
20) Nishikawa T, et al:Normalizing mitochondrial superoxide production blocks three pathways of hyperglycemia damage. Nature 404:787-790, 2000.
PubMed
P.39 掲載の参考文献
1) The DECODE study group:Glucose tolerance and mortality:comparison of WHO and American Diabetic Association diagnostic criteria. Lancet 354:617-621, 1999.
 
2) Tominaga M, et al:Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. Diabetes Care 22:920-924, 1999.
 
3) Suzuki E, et al:Prevalence and major risk factors of reduced flow volume in lower extremities with normal ankle-brachial index in Japanese patients with type 2 diabetes. Diabetes Care 26:1764-1769, 2003.
PubMed
4) Naveed Satter, et al:Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the west of Scotland coronary prevention study. Circulation 108:414-419, 2003.
 
5) Kawano H, et al:Hyperglycemia rapidly suppresses flow mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 34:146-153, 1999.
PubMed
6) Anderson R A, et al:The relationship between post-prandial lipemia, endothelial function and oxidative stress in healthy individuals and patients with type 2 diabetes. Atherosclerosis 154:475-483, 2001.
 
7) Ruige J B, et al:Insulin and risk of cardiovascular disease. A meta-analysis. Circulation 97:996-1001, 1998.
PubMed
8) National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III):Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106:3143-3421, 2002.
 
9) Libby P:Inflammation in atherosclerosis. Nature 420:868-874, 2002.
PubMed
10) 柏木厚典, 他:代謝.栄養1. 糖尿病. 内科学レビュー 2005 (酒井紀編) pp128-133.総合医学社, 東京, 2005.
 
11) Ridker P M, et al:C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events:an 8-year follow-up of 14719 initially healthy American women. Circulation 107:391-397, 2003.
 
12) Ridker P M, et al:Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347:1557-1565, 2002.
PubMed
14) Shinozaki K, et al:Oral administration of tetrahydrobiopterin prevents endothelial dysfunction and vascular oxidative stress in the aortas of insulin-resistant rats. Circ Res 87:566-573, 2000.
PubMed
15) Shimomura I, et al:Enhancede expression of PAI-1 in visceral fat:possible contributor to vascular disease in obesity. Nat Med 2:800-803, 1996.
PubMed
16) Sekine O, et al:Insulin activates CCAAT/enhancer binding Proteins and proinflammatory gene expression through the phosphatidylinositol 3-kinase pathway in vascular smooth muscle cells. J Biol Chem 277:36631-36639, 2002.
 
17) Shinozaki K, et al:Evidence for a causal role of the renin-angiotensin system in vascular dysfunction associated with insulin resistance. Hypertension 43:255-262, 2004.
PubMed
17) Oxlund H, et al:Increased aortic stiffness in patients with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 32:748-752, 1989.
PubMed
18) Airaksinen K E J, et al:Diminished arterial elasticity in diabetes:association with fluorescent advanced glycosylation end products in collagen. Cardiovasc Res 27:942-945, 1993.
 
19) Young MJ, et al:Medial artelial calcification in the feet of diabetic patients and matched non-diabetic control subjects. Diabetologia 36:615-621, 1993.
PubMed
20) Suzuki E, et al:Increased arterial wall stiffness limits flow volume in the lower extremities in type 2 diabetic patients. Diabetes Care 24:2107-2114, 2001.
PubMed
21) Matthew J, et al:Molecular understanding of hyperglycemia:s adverse effects for diabetic compucations. JAMA 288:2579-2588, 2002.
 
22) Zhou Z, et al:Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation 107:2238-2243, 2003.
PubMed
23) Sakaguchi T, et al:Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 111:959-972, 2003.
PubMed
24) Bucciarelli L G, et al:RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106:2877-2835, 2002.
 
25) Koya D, et al:Amelioration of accelerated diabetic mesangial expansion by treatment with a PKCBinhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 14:439-447, 2000.
PubMed
26) Inoguchi T, et al:High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD (P) Hoxidase in cultured vascular cells. Diabetes 49:1939-1945, 2000.
 
P.47 掲載の参考文献
1) Hotamisligil G S, et al:Adipose expression of tumor necrosis factor-alpha:direct role in obesity-linked insulin resistance. Science 259 (5091):87-91, 1993.
PubMed
2) Hotamisligil G S, et al:Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95 (5):2409-2415, 1995.
PubMed
3) Muse E D, et al:Role of resistin in diet-induced hepatic insulin resistance. J Clin Invest 114 (2):232-239, 2004.
PubMed
4) Satoh H, et al:Adenovirus-mediated chronic "hyper-resistinemia" leads to in vivo insulin resistance in normal rats. J Clin Invest 114 (2):224-231, 2004.
PubMed
5) Bajaj M, et al:Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int J Obes Relat Metab Disord 28 (6):783-789, 2004.
PubMed
6) Shimomura I, et al:Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 401 (6748):73-76, 1999.
PubMed
7) Shimomura I, et al:Enhanced expression of PAI-1 in visceral fat:possible contributor to vascular disease in obesity. Nat Med 2 (7):800-803, 1996.
PubMed
8) Matsumoto S, et al:Increased plasma HBEGF associated with obesity and coronary artery disease. Biochem Biophys Res Commun 292 (3):781-786, 2002.
PubMed
9) Arita Y, et al:Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257 (1):79-83, 1999.
PubMed
10) Maeda K, et al:cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (Adipose Most abundant Gene transcript 1). Biochem Biophys Res Commun 221 (2):286-289, 1996.
PubMed
11) Maeda N, et al:Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8 (7):731-737, 2002.
PubMed
12) Ouchi N, et al:Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 102 (11):1296-1301, 2000.
PubMed
13) Ouchi N, et al:Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103 (8):1057-1063, 2001.
 
14) Arita Y, et al:Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 105 (24):2893-2898, 2002.
PubMed
15) Okamoto Y, et al:Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106 (22):2767-2770, 2002.
PubMed
16) Hotta K, et al:Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20 (6):1595-1599, 2000.
PubMed
17) Kumada M, et al:Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23 (1):85-89, 2003.
PubMed
P.55 掲載の参考文献
1) Fujishima M, et al:Diabetes and cardiovascular disease in a prospective population survey in Japan:The Hisayama Study. Diabetes 45 (suppl 3):S14-16, 1996.
 
2) Tominaga M, et al:Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 22:920-924, 1999.
 
3) Curr Therp Res 6:219, 2000.
 
4) Matsuzaki M, et al:Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. Circ J 66:1087-1095, 2002.
PubMed
5) Mabuchi H, et al:Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease:secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT). Circ J 66:1096-1100, 2002.
 
6) Matsuzawa Y, et al:Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51, 321 Japanese hypercholesterolemic patients. Circ J 67:287-294, 2003.
PubMed
7) Brwon M S, et al:The SREBP pathway:regulation of cholesterol metabolism by proteolysis of amembrane-bound transcription factor. Cell 89:331-340, 1997.
 
8) Nagai Y:Amelioration of high fructose-induced metabolic derangements by activation of PPARa. Am J physiol Endocrinol Metab 282:E1180-1190, 2002.
 
9) Shimano H:Sterol regulatory element-inding proteins (SREBPs):transcriptional regulators of lipid synthetic genes. Prog Lipidres 40:439-352, 2001.
 
10) Ide T:SREBPs suppress IRS-2-mediated insulin signalling in the liver. Nat Cell Biol 6:351-357, 2004.
PubMed
11) Marschner I C, et al:Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study:Long-term risk stratification for survivors of acute coronary syndromes. Results from the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study. LIPID Study Investigators. J Am Coll Cardiol 38 (1):56-63, 2001.
 
12) Ballantyne CM, et al:Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 104 (25):3046-3051, 2001.
PubMed
13) Ford I, et al:The PROSPER Study Group:Prospective Study of Pravastatin in the Elderly at Risk (PROSPER):Screening Experience and Baseline Characteristics. Curr Control Trials Cardiovasc Med 3 (1):8, 2002.
 
14) ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial:Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care:The Anti-hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALL-HAT-LLT). JAMA 288 (23):2998-3007, 2002.
 
15) The FIELD Study Investigators:The need for a large-scale trial of fibrate therapy in diabetes:the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. (ISRCTN-64783481]. Cardiovasc Diabetol 3 (1):9, 2004.
 
16) Collins R, et al:Heart Protection Study Collaborative Group:Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 363 (9411):757-767, 2004.
PubMed
17) Colhoun H M, et al:CARDS investigators:Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS):multicentre randomised placebo-controlled trial. Lancet 364 (9435):685-696, 2004,
PubMed
18) Ridker P M, et al:Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol<70mg/dl and C-reactive protein<2mg/1:an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol 45 (10):1644-1648, 2005.
PubMed
P.66 掲載の参考文献
1) 日本高血圧学会高血圧治療ガイドライン作成委員会:高血圧治療ガイドライン 2004年版
 
2) Kahn R C, et al:Joslin's Diabetes Mellitus Fourteenth Edition
 
3) 片山茂裕:高血圧を合併する糖尿病. 日本臨 60 (増刊号10):411-417, 2002.
Medical*Online
4) Steinberg HO, et al:Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest 94:1172-1179, 1994.
PubMed
5) Laakso M, et al:decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. J Clin Invest 85:1844-1852, 1990.
 
6) Aizawa-Abe M, et al:Pathophysiological role of leptin in obesity-related hypertension. J Clin lnvest 105 (9):1243-1252, 2000.
 
7) Agata J, et al:High plasma immunoreactive leptin level in essential hypertension. Am J Hypertens 10:1171-1174, 1997.
PubMed
8) Stephenson K, et al:Neointimal formation after endovascular arterial injury is markedly attenuated in db/db mice. Arterioscler Thromb Vasc Biol 23:2027-2033, 2004.
 
9) Schafer K, et al:Leptin promotes vascular remodeling and neointimal growth in mice. Arterioscler Thromb Vasc Biol 24:112-117, 2004.
PubMed
10) Satoh N, et al:Leptin-to-adiponectin ratio as a potential atherogenic index in obese type 2 diabetic patients. Diabetes Care 27:2488-2490, 2004.
PubMed
11) Kurtz T W, et al:Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin H receptor antagonists:beyond the renin-angiotensin system. J Hypertens 22:2253-2261, 2004.
PubMed
12) Benson S C, et al:Identification of telmisartan as a unique angiotensin H receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43:993-1002, 2004.
PubMed
13) Sechi La, et al:the cardiac rennin-angiotensin system in STZ-induced diabetes. Diabetes 43:1180-1184, 1994.
 
14) Frustaci A, et al:Myocardial cell death in human diabetes. Circ Res 87:1123-1132, 2000.
PubMed

第3章 糖尿病合併症の診断・管理・治療

P.75 掲載の参考文献
1) Antonelli Orlidge A, et al:An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes. Proc Natl Acad Sci USA 86:4544-4548, 1989.
PubMed
2) Uemura A, et al:Recombinant angiopoietin-1 restores higher-order architecture of growing blood vessels in mice in the absence of mural cells. J Clin Invest 110:1619-1628, 2002.
 
3) Takagi H, et al:New surgical approach for removing massive foveal hard exudates in diabetic macular edema. Ophthalmology 106:249-256, 1999.
PubMed
4) Yamamoto Y, et al:Roles of the AGE-RAGE system in vascular injury in diabetes. Ann NY Acad Sci 902:163-170, 2000.
PubMed
5) Miyamoto K, et al:Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular odhesion molecule-1 inhibition. Proc Natl Acad Sci USA 96:10836-10841, 1999.
PubMed
6) Oh H, et al:Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells. J Biol Chem 274:15732-15739, 1999.
PubMed
7) Oh H, et al:Selective induction of neuropilin-1 by vascular endothelial growth factor (VEGF):Anovel mechanism contributing to VEGF-induced angiogenesis. Proc Natl Acad Sci USA 99:383-388, 2002.
 
8) Watanabe D, et al:Erythropoietin is a potential retinal angiogenic factor independent of vascular endothelial growth factor in proliferative diabetic retinopathy. New Eng JMed. (in press)
 
9) Davis M D:Vitreous contraction in Prohferative diabetic retinopathy. Arch Ophthalmol 74:741-751, 1965.
PubMed
10) 福田雅俊:糖尿病網膜症の病期分類. 眼科 MOOK46, 糖尿病と眼科治療 117-125, 金原出版, 1991.
 
11) Early Treatment Diabetic Retinopathy Study Research Group:Fundus Photographic Risk Factors for Progression of Diabetic Retinopathy ETDRS Report Number 12. Ophthalmology 98:823-833, 1991.
 
12) Wilkinson C P, et al:Proposed International Clinical Diabetic Retinopathy and Diabetic Macular Edema Disease Sevirity Scales. Ophthalmology 110:1677-1682, 2003.
 
P.85 掲載の参考文献
1) Frank R N:Diabetic retinopathy. N Engl JMed 350 (1):48-58, 2004.
 
2) The DCCT Research Group:The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (14):977-986, 1993.
 
3) UKPDS Group:Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2diabetes (UKPDS 33). Lancet 352:837-853, 1999.
 
4) The DCCT/EDIC Research Group:Retinopathy and nephropathy in the patients with type 1l diabetes four years after a trial of intensive therapy. N Engl J Med 342 (6):381-389, 2000.
 
5) Shichiri M, et al:Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 23 (Suppl 2):B21-B29, 2000.
 
6) UKPDS Group:Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 38. BMJ 317:703-712, 199&
 
7) Schrier R W, et al:Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 61 (3):1086-1097, 2002.
PubMed
8) Chaturvedi N, et al:Effect of lisinopril on progression of retinopathy in normotensive people with type l diabetes. Lancet 351:28-31, 1998.
 
9) Porta M, et al:Current approaches and perspectives in the medical treatment of diabetic retinopathy. Pharmacol Ther 103 (2):167-177, 2004.
PubMed
10) Fong D S, et al:Diabetic retinopathy. Diabetes Care 27 (10):2540-2553, 2004.
PubMed
11) 糖尿病診療ガイドライン:糖尿病網膜症の治療. 糖尿病 45 (Suppl 1):39-42, 2002.
 
12) Gaede P, et al:Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 (5):383-393, 2003.
PubMed
13) Van Wijngaarden P, et al:Inhibitors of ocular neovascularization. Promises and potential problems. JAMA 293 (12):1509-1513, 2005.
PubMed
P.91 掲載の参考文献
1) 日本糖尿病学会:科学的根拠に基づく糖尿病 診療ガイドライン, p57-65, 南江堂, 2004.
 
2) 厚生省:糖尿病調査研究報告書 (平成3年度), p33-38 (疫学統計).
 
3) Klein R, et al:The Wisconsin Epidemiologic Study of Diabetic Retinopathy:II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 102:520-526, 1984.
PubMed
4) Klein R, et al:The Wisconsin Epidemiologic Study of Diabetic Retinopathy III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 102:527-532, 1984.
PubMed
5) Stratton I M, et al:Risk factor for incidence and progression of retinopathy in Type 2 diabetes over 6 years from diagnosis (UKPDS 50). Diabetologia 44:156-163, 2001.
PubMed
6) The Diabetes Control and Complications Trial (DCCT) Research Group:The effect of intensive treatment of diabetes on the development and progression of long-term complication in insulin-dependent diabete mellitus. N Engl J Med 329:977-986, 1993.
 
7) Ohkubo Y, et al:Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus:arandomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117, 1995.
 
8) The Diabetes Control and Complications Trial (DCCT) Research Group:Eary worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 116:874-886, 1998.
 
9) Kohner E M, et al:Relationship between the severity of retinopathy and progression to photocoagulation in patient with Type 2 diabetes mellitus in the UKPDS (UKPDS 52). Diabet Med 18:178-184, 2001.
PubMed
10) Diabetic Retinopathy Study Research Group:Photocoagulation treatment of proliferative diabetic retinopathy:The second report of diabetic retinopathy study findings. Ophthalmology 85:82-106, 1978,
 
11) Early Treatment Diabetic Retinopathy Study Research Group:Early photocoagulation for diabetic retinopathy:ETDRS report number 9. Ophthalmology 98:766-785, 19919) Diabetic Retinopathy Study Research Group:Photocoagulation treatment of proliferative diabetic retinopathy:The second report of diabetic retinopathy study findings. Ophthalmology 85182-106, 1978.
 
12) The Diabetic Retinopathy Vitrectomy Study Research Group:Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Four-year result of a randomized trial; (DRVS 5). Arch Ophthalmol 108:958-964, 1990.
 
13) The Diabetic Retinopathy Vitrectomy Study Research Group:Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Results of randomized trial. (DRVS 3). Ophthalmology 95:1307-1320, 1988.
 
P.100 掲載の参考文献
1) Krolewski A S, et al:The changing natural history of nephropathy in type 1 diabetes. Am J Med 78:785-794, 1985.
PubMed
2) Quinn M, et al:Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia 39:940-945, 1996.
PubMed
3) Fujisawa T, et al:Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia 41:47-53, 1998.
PubMed
4) Hadjadj S, et al:Prognostic value of angiotensin-I convertlng enzyme I/D morphism for nephropathy in type betes mellitus:aprospective study. Soc Nephrol 12:541-549, 2001.
 
5) Araki S, et al:APOE polymorphism and the progression of diabetic nephropathy in Japanese subjects with type 2 diabetes:results of a prospective observational follow-up study. Diabetes Care 26:2416-2420, 2003.
PubMed
6) Haneda M, et al:Overview of glucose signaling in mesangial cells in diabetic nephropathy. J Am Soc Nephrol 14:1374-1382, 2003.
PubMed
7) Koya D, et al:Protein kinase C activation and the development of diabetic complications. Diabetes 47:859-866, 1998.
PubMed
8) Ishii H, et al:Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 272:728-731, 1996.
PubMed
9) Koya D, et al:Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest 100:115-126, 1997.
PubMed
10) Koya D, et al:Amelioration of accelerated diabetic mesangial expansion by treatment with a PKCb inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 14:439-447, 2000.
 
11) Ziyadeh F N, et al:Long-term prevention of renal insufflciency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97:8015-8020, 2000.
 
12) Kanasaki K, et al:N-Acetyl-seryl-aspartyl-lysyl-proline inhibits TGF-beta-mediated plasminogen activator inhibitor-1 expression via inhibition of Smad pathway in human mesangial cells. J Am Soc Nephrol 14:863-872, 2003.
PubMed
13) Shibuya K, et al:N-Acetyl-Seryl-Aspartyl-Lysyl-Proline prevents renal insufficiency and mesangial matrix expansion in diabetic db/db mice. Diabetes 54:838-845, 2005.
PubMed
14) 糖尿病性腎症合同委員会:糖尿病性腎症病期分類厚生省案の改定について. 糖尿病 44:623, 2001.
 
P.107 掲載の参考文献
1) 日本透析医学会:図説わが国の慢性透析療法の現況 (2003年12月31日現在〉, p12. 2004.
 
2) Adler A I, et al:Development and progression of nephropathy in type 2 diabetes:the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63:225-232, 2003.
PubMed
3) 四方賢一:わかる糖尿病性腎症 (槙野博史 編), p47-55. 診断と治療社, 東京, 2002.
 
4) Ohkubo Y, et al:Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus-a randomized prospective 6-year study-. Diabetes Res Clin Pract 28:103-117, 1995.
PubMed
5) American Diabetes Association:Clinical practice recommendations. Diabetes Care Supple 1:S33-S49, 2002.
 
6) 日本高血圧学会高血圧治療ガイドライン作成委員会編:高血圧治療ガイドライン2004, p47-49. ライフサイエンス出版株式会社, 東京, 2004.
 
7) The Microalbuminuria Captopril Study Group:Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia 39:587-593, 1996.
 
8) Parving H H, et al:The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878, 2001.
PubMed
9) Gaede P, et al:Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria:the Steno type 2 randomized study. Lancet 20:617-622, 1999.
 
10) Fioretto P, et al:Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 339:69-75, 1998.
PubMed
11) Lewis E J, et al:The effect of angiotensinconverting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993.
 
12) Wilmer W A, et al:Remission of nephritic syndrome in type 1 diabetes:long term follow-up of patients in the Captopril Study. Am J Kidney Dis 34:308-314, 1999.
 
13) Lewis E J, et al:Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes, N Engl J Med 345:851-860, 2001,
PubMed
14) Brenner B M, et al:Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, N Engl J Med 345:861-869, 2001.
PubMed
15) Rossing K, et al:Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy:arandomized double-blind crossover trial. Diabetes Care 26:2268-2274, 2003.
 
16) Jacobsen P, et al:Additive effect of ACE inhibition and angiotensin n receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol 14:992-999, 2003.
 
17) Andersen N H, et al:Dual blockade of the renin angiotensin system in diabetic and nondiabetic kidney disease. Curr Hypertens Rep 6:369-376, 2004.
PubMed
18) Pedrini M T, et al:The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases:a meta-analysis. Ann Intern Med 124:627-632, 1996.
PubMed
P.114 掲載の参考文献
1) Zatz R, et al:Prevention of diabetic glomerulopathy by pharmacological ameriolation of glomerular capillary hypertension. J Clin Invest 77:1925-1930, 1986.
 
2) Lewis E J, et al:The effect of angiotensinconverting enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-14621993.
 
3) Katayama S, et al:Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus:Arandomized controlled study (JAPAN-IDDM). Dib Res Clin Pract 55:113-121, 2002.
 
4) Brenner B M, et al:Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001.
PubMed
5) Lewis E J, et al:Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001.
PubMed
6) Parving H, et al:The effect of irbesartan on the progression of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878, 2001.
PubMed
7) Viberti G, et al:Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure-independent effect. Circulation 106:672-678, 2002.
PubMed
8) Barnett A H, et al:Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351:1952-1961, 2004.
PubMed
9) Lewis J B, et al:Effect of intensive blood pressure control on the course of type l diabetic nephropathy. Collaborative Study Group. Am J Kidney Dis 34:809-817, 1999.
 
10) Mogensen C E, et al:Randomised controlled trila of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes:the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 321:1440-1444, 2000.
 
P.123 掲載の参考文献
1) Brenner B M:Retarding the progression of renal disease. Kidney Int 64:370-378, 2003.
PubMed
2) Rugeneti P, et al:Retarding progression of chronic renal disease:The neglected issue of residual proteinuria. Kidney Int 63:2254-2261, 2003.
PubMed
3) Gaede P, et al:Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria:the Steno type 2 randomized study. Lancet 353:617-622, 1999.
PubMed
4) Hebert L A, et al:Renoprotection:One or many therapies? Kidney Int 59:1211-1226, 2001.
PubMed
5) Manto A, et al:Effects of intensive treatment on diabetic nephropathy in patients with type 1 diabetes. Kidney Int 47:231-235, 1995.
 
6) Fioretto P, et al:Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 339:69-75, 1998.
PubMed
7) Isshiki K, et al:Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes 49:1022-1032, 2000.
PubMed
8) McCarthy K J, et al:Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion. Kidney Int 58:2341-2350, 2000.
PubMed
9) Christensen P K, et al:Impaired autoregulation of GFR in hypertensive non-insulin dependent diabetic patients. Kidney Int 52:1369-1373, 1997.
PubMed
10) Guidehnes Subcommittee:1999 World Health Organization International Society of Hypertension guidelines for the management of hypertension. JHypertension 17:151-183, 1999.
 
11) Lewis E J, et al:The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993.
PubMed
12) Brenner B, et al:Renoprotective benefits RAS inhibition:From ACEi to angiotensin II antagonists. Kidney Int 57:1803-1817, 2000.
PubMed
13) Boffa J-J, et al:Regression of renal vascular and glomerular fibrosis:role of giotensin II receptor antagonism and trix metalloproteinases. J Am Soc Nephrol 14:1132-1144, 2003.
 
14) Dworkin L D, renal growth and stabilize injury in with established renal disease. Nephrol 7:437-432, 1996.
 
15) Okada T, et al:The influence of dietary salt and protein intake on the protelnuria in patients with IgA nephropathy. 日病態栄会誌 4:19-27, 2001.
 
16) 日本腎臓学会:腎疾患患者の生活指導.食事療法に関するガイドライン. 日腎誌 39:1-37, 1997.
 
17) Brenner B M, et al:The hyperfiltration theory:aparadigm shift in nephrology. Kidey Int 49:1774-1777, 1996.
 
18) 岡田知也, 他:腎不全期糖尿病性腎症における蛋白制限の進行抑制効果に及ぼす蛋白尿の影響. 日腎誌 42:365-373, 2000.
 
19) Mohanram A, et al:Anemia and end-stagerenal disease in patients with type 2 diabetes and nephropathy. Kidney Int 66:1131-1138, 2004.
 
20) Bonnet F, et al:Potential influence of lipids in diabetic nephropathy:insights from experimental data and clinical studies. Diab Metab 26:254-264, 2000.
 
21) Nakao T, et al:Low-density lipoprotein apheresis retards the progression of hyperlipidemic overt diabetic nephropathy. Kidney Int 56:s206-s209, 1999.
 
22) 日本透析医学会統計調査委員会:わが国の慢性透析の現況 (2003年12月31日現在). 透析会誌 38:1-16, 2005.
 
23) United States Renal Data System:Incidence & prevalence of ESRD. Am J Kidney Dis 42 (suppl 5):s47-s60, 2003.
 
24) United States Renal Data System:Diabetes and pre-ESRD diabetic care. Am J Kidney Dis 45 (suppl 1):s38-s39, 2003.
 
25) 川口良人, 他:血液透析-透析導入基準の見直しと最近の考え方. 内科 72:301-307, 1993.
 
26) NKF-DOQI Clinical Practice Guidelines for Peritoneal Dialysis Adequacy:Initiation of dialysis. Am J Kid Dis 30:s70-73, 1997.
 
27) Okada T, et al:Predialysis factors related to Prognosis in type2 dibetic patients on chronic dialysis in Japan. Nephrology 7:250-256, 2002.
 
28) Okada T, et al:Physical functional status and factors contributing to disability in Japanese chronic dialysis patients. Nephrology 4:195-203, 1998.
 
P.134 掲載の参考文献
1) 槙野博史:糖尿病性腎症の早期診断と治療. 日内会誌 93:471-476, 2004.
 
2) 岡田震一, 他:糖尿病性腎症-積極的治療による「不可逆」からの回復. 内科 91:119-123, 2003.
 
3) 出浦照國:糖尿病腎症管理への新しいガイドラインの試み. 糖尿合併会誌 18:67-70, 2004.
 
4) 出浦照國:食事療法のサイエンスとアート. Medical Practice 18:1687-1692, 2001.
Medical*Online
5) Dikow R et al:Nutritional requirements of diabetics with nephropathy. In:Handbook of Nutrition and the Kidney 4th ed (Mitch W E, et al, eds), 157-177, Lippincott Williams &Wilkins, Philadelphia, 2002.
 
6) Lindholm B, et al:Uremic toxicity. In:Nutritional Mnagement or Renal Disease 2nd ed. (Kopple L D, et al, eds), p64-98 Lippin-cott Williams & Wilkins, Philadelphia, 2004.
 
7) Ideura T, et al:Amino acid profiles can be maintained in chronic renal failure with a very low protein diet without supplementation of essential amino acids or keto analogues. In:Advances in Renal Nutrition and Metabolism (DeSant N G, et al, eds), p55-58, Bios, Naples, 1997.
 
8) Fouque D:Influence of dietary protein intake on the progression of chronic renal insufficiency. In:Nutritional Mnagement or Renal Disease 2nd ed.(Kopple L D, et al, eds), p241-259. Lippincott Williams & Wilkins, Philadelphia, 2004.
 
9) 出浦照國:慢性進行性腎不全-食事療法. 内科 89:1215-1218, 2002.
 
10) Ideura T, et al:Effect of nonsupplemented low-protein diet on very late stage CRF. Am J Kidney Dis 41:31-34, 2003.
 
11) 島居美幸, 他:慢性腎不全に対するたんぱく質20g食の臨床効果と食事内容の検討. 日病態栄会誌 7:35-45, 2004.
 
12) 出浦照國:腎疾患患者の食事援助, 治療用特殊食品の利用-低たんぱく食品. 臨透析 13:1451-1460, 1998.
 
13) 出浦照國:低蛋白治療用特殊食品とは?肥満と糖尿 3:462-465, 2004.
Medical*Online
14) 出浦照國, 他:糖尿病性腎症による血液透析患者に対する食事療法. 透析医会誌 24:1625-1628, 1987.
 
15) Jenkins, D J A:Low glycemic index in hyperlipidemia:use of nutritional starchy foods. Am J Clin Nutr 46:66-71, 1987.
 
16) 出浦照國, 他:慢性腎不全における低たんぱく食のコンプライアンスの研究. 厚生省特定疾患進行性腎障害調査研究班平成7年度研究業績 黒川清編 p51-53, 1996.
 
17) 島居美幸, 他:保存期慢性腎不全における低たんぱく食に対するコンプライアンスの検討. 日病態栄会誌 4:41-47, 2001.
 
18) 出浦照國:食品成分表を栄養指導に生かそう. 食生活 98:86-91, 1998.
 
19) 厚生省平成5年度糖尿病調査研究班報告書 1994.
 
P.142 掲載の参考文献
1) Thomas P K:Classification, differential diagnosis, and staging of diabetic peripheral neuropathy. Diabetes 46 (Suppl 2):S54-57, 1997.
 
2) Suzuki E, et al:1H-and 31P-magnetic resonance spectroscopy and imaging as a new diagnostic tool to evaluate neuropathic foot ulcers in Type II diabetic patients. Diabetologia 43:165-172, 2002.
 
3) Eaton S E, et al:Increased sural nerve epineurial blood flow in human subjects with painful diabetic neuropathy. Diabetologia 46:934-939, 2003
PubMed
4) Said G, et al:Inflammatory vasculopathy in multifocal diabetic neuropathy. Brain 126:376-385, 2003.
PubMed
5) Uehara K, et al:Effects of polyol pathway hyperactivity on protein kinase C activity, nociceptive peptide expression, and neuronal structure in dorsal root ganglia in diabetic mice. Diabetes 53:3239-3247, 2004.
PubMed
6) Schratzberger P, et al:Reversal of experimental diabetic neuropathy by VEGF gene transfer. J Clin Invest 107:1083-1092, 2001.
PubMed
7) Isner J M, et al:VEGF gene transfer for diabetic neuropathy. Hum Gene Ther 12:1593-1594, 2001.
PubMed
8) Koike H, et al:Enhanced angiogenesis and improvement of neuropathy by cotransfection of human hepatocyte growth factor and prostacyclin synthase gene. FASEB J 17:779-781, 2003.
PubMed
9) Kato N, et al:Nonviral gene transfer of human hepatocyte growth factor improves streptozotocin-induced diabetic neuropathy in rats. Diabetes 54:846-854, 2005.
PubMed
10) Birrell A M, et al:Functional and structural abnormalities in the nerves of type I diabetic baboons:amminoguanidine treatment does not improve nerve function. Diabetologia 43:110-116, 2000
 
11) Wada R, et al:Effects of OPB-9195, anti-glycation agent, on experimental diabetic neuropathy. Eur J Clin Invest 31:513-520, 2001.
PubMed
12) Schmeichel A M, et al:Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy. Diabetes 52:165-171, 2003.
PubMed
13) Kishi M, et al:Morphometry of dorsal root ganglion in chronic experimental diabetic neuropathy. Diabetes 51:819-824, 2002.
PubMed
14) Kim H, et al:PKCB selective inhibitor LY333531 attenuates diabetic hyperalgesia through ameliorating cGMP level of dorsal root ganglion neurons Diabetes 52:2102-2109, 2003.
 
15) Yamagishi S, et al:Differential influence of increased polyol pathway on protein kinase C expressions between endoneurial and epineurial tissues in diabetic mice. J Neurochem 87:497-507, 2003.
PubMed
16) Sakaue Y, et al:Amelioration of retarded neurite outgrowth of dorsal root ganglion neurons by overexpression of PKCδ in diabetic rats. Neuroreport 14:431-436, 2003.
 
17) Yasuda H, et al:Diabetic neuropathy and nerve regeneration. Prog Neurobiol 69:229-285, 2003.
PubMed
18) Goss J R, et al:Herpes simplex-mediated gene transfer of nerve growth protects against peripheral neuropathy in strep tozpocin-induced diabetes in the mouse. Diabetes 51:2227-2232, 2002.
 
19) Middlemas A, et al:Enhanced activation of axonally transported stress-activated protein kinases in peripheral nerve in diabetic neuropathy is prevented by neurotrophin-3. Brain 126:1671-1682, 2003.
PubMed
20) Brussee V, et al:Direct insulin signaling of neurons reverses diabetic neuropathy. Diabetes 53:1824-1830, 2004.
PubMed
P.153 掲載の参考文献
1) The Diabetes Control and Complications Trial Research Group:The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993.
 
2) Ohkubo Y, et al:Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus:arandomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117, 1995.
 
3) Shichiri M, et al:Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients, Diabetes Care 23 (Suppl 2):B21-B29, 2000.
 
4)Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type ldiabetes mellitus on development and progression of diabetic nephropathy:The Epidemiology of diabetes interventions and complications (EDIC) study. JAMA 290:21592167, 2003.
 
5) Greene D A, et al:Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Neurology 53:580-591, 1999.
PubMed
6) Hotta N, et al:Clinical efficacy of fidarestat, anovel aldose reductase inhibitor, for diabetic peripheral neuropathy. Diabetes Care 24:1776-1782, 2001.
 
7) Bril V, et al, and The AS-3201 Study Group:Aldose reductase inhibition by AS-3201in sural nerve from patients with diabetic sensorimotor polyneuropathy. Diabetes care 27:2369-2375, 2004.
 
8) Koya D, et al:Protein kinase C activation and the development of diabetic complications. Diabetes 47:859-866, 1998.
PubMed
9)Nakamura J, et al:Aprotein kinase C-B-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes 48:2090-2095, 1999.
 
10) Kamiya H, et al:Polyol pathway and protein kinase C activity of rat Schwannoma cells. Diabetes Metab Res Rev 19:131-139, 2003.
 
11) Yamagishi S, et al:Differential influence of increased polyol pathway on protein kinase C expressions between endoneurial and epineurial tissues in diabetic mice. J Neurochem 87:497-507, 2003.
PubMed
12) Uehara K, et al:Effects of polyol pathway hyperactivity on protein kinase C activity, nociceptive peptide expression, and neuronal structure in dorsal root ganglia in diabetic mice. Diabetes 53:3239-3247, 2004.
PubMed
13) Obrosova I G, et al:Role of poly (ADP-ribose) polymerase activation in diabetic neuropathy. Diabetes 53:711-720, 2004.
PubMed
14) Obrosova I G, et al:Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly (ADP-ribose) polymerase activation in tissue sites for diabetes complications. Diabetes 54:234-242, 2005.
PubMed
15) Tutuncu N B, et al:Reversal of defective nerve conduction with vitamin E supplementation in type 2 diabetes:apreliminary study. Diabetes Care 21:1915-1918, 1998.
 
16) Ziegler D, et al:Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid:ameta-analysis. Diabet Med 21:114-121, 2004
 
17) Yonekura H, et al:Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 370:1097-1109, 2003.
PubMed
18) Gaede P, et al:Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383-393, 2003.
PubMed
19) Ekberg K, et al:Amelioration of sensory nerve dysfunction by C-peptide in patients with type 1 diabetes. Diabetes 52:536-541, 2003.
 
20) Calcutt N A, et al:Therapeutic efficacy of sonic hedgehog protein in experimental diabetic neuropathy. Clin Invest 111:507-514, 2003.
PubMed
21) Kato N, et al:Nonviral gene transfer of human hepatocyte growth factor improves treptozotocin-induced diabetic neuropathy in rats. Diabetes 54:846-854, 2005.
 
22) Naruse K, et al:Therapeuric neovascularization using cord blood-derived endothelial progenitor cells for diabetic neuropathy. Diabetes 54:2005. (ln press)
 
P.159 掲載の参考文献
1) 藤島正敏:日本人の脳血管障害. 日内会誌 85:1407-1418, 1996.
 
2) 清原裕, 他:脳梗塞の危険因子. 脳梗塞 (藤島 正敏監修) p71-86, 中山書店, 東京, 2000.
 
3) Hess D C, et al:HMG-CoA reductase inhibitors (statins). A promising approach to stroke prevention. Neurology 54:790-796, 2000.
PubMed
4) Kannel W B, et al:Diabetes and cardiovascular disease. The Framingham study. JAMA 241:2035-2038, 1979.
PubMed
5) Davis P H, et al:Risk factors for ischemic stroke:Aprospective study in Rochester, Minnesota. Ann Neurol 22:319-327, 1987.
 
6) Burchfiel C M, et al:Glucose intolerance and 22-year stroke incidence. The Honolulu Heart Program. Stroke 25:951-957, 1994.
PubMed
7) 藤島正敏:高齢者の心血管病-久山町研究から. 日老医誌 36:16-21, 1999.
 
8) Selvin E, et al:Meta-analysis:glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 141:421-431, 2004.
PubMed
9) Gaede P, et al:Intensive integrated therapy of type 2 diabetes. Implications for long term prognosis. Diabetes 53 (Suppl. 3):S39-S47, 2004.
 
10) Amarenco P, et al:Statins in stroke prevention and carotid atherosclerosis. Systematic review and up-to-date mata-analysis. Stroke 35:2902-2909, 2004.
 
11) Aronson S M:Intracranial vascular lesions in patients with diabetes mellitus. J Neuropathol Exp Neurol 32:183-196, 1973.
PubMed
12) 亀山正邦:糖尿病と脳血管障害. 脳卒中のすべて (沖中重雄編), p163, 南江堂, 東京1971.
 
13) Iwase M, et al:Stroke topography in diabetic and nondiabetic patients by magnetic resonance imaging. Diabetes Res Clin Pract 42:109-116, 1998.
PubMed
14) Kameda W, et al:Lateral and medial medullary infarction:Acomparative analysis of 214patients. Stroke 35:694-699, 2004.
 
15) Olsson T, et al:Prognosis after stroke in diabetes patients. A controlled prospective study. Diabetelogia 33:244-249, 1990.
PubMed
16) Arboix A, et al:Diabetes is an independent risk factor for in-hospital mortality from acute spontaneous intracerebral hemorrhage. Diabetes Care 23:1527-1532, 2000.
PubMed
17) Tuomilehto J, et al:Diabetes mellitus as a risk factor for death from stroke. Prospective study of the middle-aged Finnish population. Stroke 27:210-215, 1996.
PubMed
18) Craig J, et al:Epidemiology and costs of acute hospital care for cerebrovascular disease in diabetic and nondiabetic populations. Stroke 28:1142-1146, 1997.
 
19) Megherbi S E, et al:Association between diabetes and stroke subtype on survival and functional outcome 3 months after stroke:data from the European BIOMED Stroke Project. Stroke 34:688-694, 2003.
PubMed
20) Hankey G J:Long-term outcome after ischaemic stroke/transient ischaemic attack. Cerebrovasc Dis 16 (Suppl 1):14-19, 2003.
PubMed
21) Alter M, et al.:Stroke recurrence in diabetics:Does control of blood glucose reduce risk? Stroke 28:1153-1157, 1997.
PubMed
22) UK Prospective Diabetes Study (UKPDS) Group:Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998.
 
23) UK Prospective Diabetes Study Group:Tight blood pressure control and risk of macrovascular complications in type 2 diabetes:UKPDS 38. Brit Med J 317:703-713, 1998.
 
24) Heart Outcomes Prevention Evaluation (HOPE) Study Investigators:Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus:results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253-259, 2000.
 
P.169 掲載の参考文献
1) 脳卒中合同ガイドライン委員会:脳卒中治療ガイドライン2004, 日本脳卒中学会/日本脳神経外科学会 (脳卒中の外科学会) /日本神経学会/日本神経治療学会/日本リハビリテーション医学会, (篠原幸人.他編). 協和企画, 2004.
 
2) 内山真一郎:脳梗塞の危険因子-最近の話題と新展開-. 臨神経 42:1064-1068, 2002.
 
3) Kannel W B, et al:Diabetes and cardiovascular disease. The Framingham Study. JAMA 241:2035-2038, 1979.
PubMed
4) Abbott R D, et al:Diabetes and the risk of stroke. The Honolulu Heart Program. JAMA 257:949-952, 1987.
PubMed
5) Singer D E, et al:Association of HbA1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes 41:202-208, 1992.
PubMed
6) 大村隆夫, 他:一般住民の22年間追跡調査 における耐糖能異常と脳卒中発症の関連. 久山町研究. 糖尿病 36:17-24, 1993.
 
7) 脳梗塞急性期医療の実態に関する研究班 (主任研究者:山口武典):脳梗塞急性期医療の実態に関する研究, 健康科学総合研究事業研究報告書, 2001.
 
8) 小林祥泰編:脳卒中データバンク, 中山書店, 東京, 2003.
 
9)山本康正:BADの概念とその臨床的意義, 進行性脳卒中とBAD (峰松一夫編), p22-41, 医薬ジャーナル社, 東京, 2004,
 
10) Atrial Fibrillation Investigators:Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation:analysis of pooled data from five randomized clinical trials. Arch Intern Med 154:1949, 1994.
 
11) UK Prospective Diabetes Study (UKPDS) Group:Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 38. Br Med. J 317:703-713, 1998.
 
12) 日本高血圧学会高血圧治療ガイドライン作成委員会:高血圧治療ガイドライン 2004年版 (日本高血圧学会高血圧治療ガイドライン作成委員会編). 日本高血圧学会, 2004.
 
13) Chobanian A V, et al:The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA 289:2560-2572, 2003.
PubMed
14) Kothari V, et al:UKPDS 60. Risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 33:1776-1781, 2002.
PubMed
15) Gaede P, et al:Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New Engl J Med 348:383-393, 2003.
PubMed
16) Colhoun H M, et al:Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS):multicentre randomized plabebocontrolled trial. Lancet 364:685-696, 2004.
PubMed
17) The DECODE Study Group:glucose tolerance and cardiovascular mortality. Comparison of fasting and 2-hour diagnosticcriteria. Arch Intern Med 161:397-404, 2001.
 
18) The DECODE Study Group:Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 26:688-696, 2003.
 
19) Kerman W N, et al:lnsulin resistance and risk of stroke. Neurology 59:809-815, 2002,
 
20) 平方秀樹:慢性血液透析患者における脳血管障害. 日透析医会誌 18:327-336, 2003.
 
21) Uchiyama S, et al:Alterations of platelet, coagulation, and fibrinolysis markers in patients with acute ischemic stroke. Semin Thromb Hemost 23:535-541, 1997.
PubMed
22) 循環器疾患の診断と治療に関するガイドライン (2002-2003年度合同研究班報告). 循環器疾患における抗凝固.抗血小板療法に関するガイドライン. Circulation J 68 (Sup-pl. IV):1153-1230, 2004.
 
23) 内山真一郎:糖尿病による脳神経合併症. 脳神経外科救急看護マニュアル, ブレインナーシング 夏期増刊:233-239, 1999.
 
24) 内山真一郎:脳血管障害. 糖尿病合併症-どう対処するか-(岩本安彦編), p188-195, 中外医学社, 東京, 2002.
 
P.177 掲載の参考文献
1) Kannel W B:CHD risk factors:a Framingham study update. Hosp Pract (Off Ed) 25:119-127, 130, 1990.
 
2) Lundberg GD:MRFIT and the goals of The Journal JAMA 248:1501, 1982.
PubMed
3) Haffner S M, et al:Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234, 1998
PubMed
4) Fujishima M, et al:Diabetes and cardiovascular disease in a prospective population survey in Japan:The Hisayama Study, Diabetes 45 (Suppl 3):S14-16, 1996.
 
5) Sone H. et al:[Prevention and therapeutic strategy of metabolic syndrome-implications from the interim results of Japan Diabetes Complications Study (JDCS) ]. Nippon Rinsho 62:1150-1157, 2004.
PubMed
6) The International Colaborative Group:Joint Discussion. J Chron Dis 32:829-837, 1977.
 
7) 岩瀬孝:糖尿病の冠硬化の進展に及ぼす影響. 循環器Today 1:587-592, 1997.
 
8) Savage M P, et al:Acute myocardial infarction in diabetes mellitus and significance of congestive heart failure as a prognostic factor. Am J Cardiol 62:665-669, 1988
PubMed
9) McGuire D K, et al:Diabetes and ischemic heart disease. Am Heart J 138:S366-375, 1999.
PubMed
10) 葛西隆敏:糖尿病における心疾患の診断と治療. 最新医 59 (1):42-51, 2004,
Medical*Online
11) American Diabetes Association:Standards of medical care for patients with diabetes mellitus. Diabetes Care 26 (suppl l):S33-S50, 2003.
 
12) Giri S, et al:Impact of diabetes on the risk stratification using stress single-photon emission computed tomography myocardial perfusion imaging in patients with symptoms suggestive of coronary artery disease. Circulation 105:32-40, 2002.
PubMed
13) Crawford M H, et al:ACC/AHA guidelines for ambulatory electrocardiography:executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on practice guideline (committee to revise the guidelines for ambulatory electrocardiography). Circulation 24:886-893, 1999.
 
14) Lemp G F, et al:Association between severity of diabetes mellitus and coronary artery atherosclerosis. Am J Cardiol 60:1015-1019, 1987.
PubMed
15) Ishihara M, et al:Impact of diabetes mellitus on long-term survival after acute myocardial infarction in patients with single vessel disease. Heart 86:133-138, 2001.
PubMed
16) Margolis J R, et al:Clinical features of unrecognized myocardial infarction-silent and symptomatic. Eighteen year follow-up:the Framingham study. Am J Cardiol 32:1-7, 1973.
PubMed
17) Kornowski R et al:Paradoxic decreases in atherosclerotic plaque mass in insulintreated diabetic patients. Am J Cardiol 81:1298-1304, 1998.
 
18) Mintz G, et al:Multiple versus single coronary plaque ruptures detected by intravascular ultrasound in stable and unstable angina pectoris and in acute myocardial infarction. Am J Cardiol 91:1333-1335, 2003.
PubMed
P.187 掲載の参考文献
1) Carrozza J p, et al:Restenosis After Arterial Injury Caused by Coronary Stenting in Patients With Diabetes Mellitus. Ann Intern Med 118:344-349, 1993. Stein B, et al:Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 91:979-989, 1995.
 
2) O'Neill W W:Multivessel balloon angioplasty should be abandoned in diabetic patients. J Am Coll Cardiol 31:20-22, 1998.
 
3) Stein B, et al:Influence of diabetes mellituson early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 91:979-989, 1995.
 
4) Kip K E, et al:The National Heart, Lung, and Blood Institue Precutaneous Transluminal Coronary Angioplasty registry. Circulation 94:1818-1825, 1996.
 
5) Elezi S, et al:Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll cardiol 32:1866-1873, 1998.
PubMed
6) Van Belle E, et al:Restenosis rates in diabetic patients:acomparison of coronary stenting and balloon angioplasty in native coronary vessels. Circulation 96:1454-1460, 1997.
 
7) 谷川高士, 他:多枝疾患, に対するステント治療後の長期予後-糖尿病患者と非糖尿病患者との比較検討-. 第49回日本心臓病学会, 2001.
 
8) Carson J L, et al:Diabetes mellitus increases short-term mortality and morbidity in patients undergoing coronary artery bypass graft surgery. J Am Coll Cardiol 40:418-423, 2002.
PubMed
9) Barsness G W, et al:Relationship Between Diabetes Mellitus and Long-term Survival After Coronary Bypass and Angioplasty. Circulation 96:2551-2556, 1997.
PubMed
10) BARI:Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med 335 (4):217-225, 1996.
 
11) King SB 3rd, et al:Arandomized trial comparing coronary angioplasty with coronary bypass surgery. Emory Angioplasty versus Surgery Trial (EAST). N Engl JMed 331 (16):1044-1050, 1994.
 
12) Henderson R A, et al:Long-term results of RITA-1 trial:clinical and cost comparisons of coronary angioplasty and coronaryartery bypass grafting, Randomised Intervention Treatment of Angina. Lancet 352 (9138):1419-1425, 1998.
 
13) First-year results of CABRI (Coronary Angioplasty versus Bypass Revascularisation Investigation). CABRI Trial Participants. Lancet 346 (8984):1179-1184, 1995.
PubMed
14) King S B 3rd, et al:Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST). J Am Coll Cardiol 35 (5):1116-1121, 2000.
 
15) The BARI Investigators:Seven-Year Outcome in the Bypass Angioplasty Revascularization Investigation (BARI) By Treatment and Diabetic Status. JAm Coll Cardiol 35:1122-1129, 2000.
 
16) Legrand V M, et al:Three year outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease. Circulation 109:1114-1120, 2004.
PubMed
17) Abizaid A, et al:Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients:insights from the Arterial Revascularization Therapy Study (ARTS) trial. Circulation 104 (5):533-538, 2001.
PubMed
18) Sedlis S P, et al:Percutaneous coronary intervention versus coronary bypass graft surgery fbr diabetic patients with unstable angina and risk factors for adverse outcomes with bypass:outcome of diabetic patients in the AWESOME randomized trial and registry. J Am Coll Cardiol 40:1555-1566, 2002.
 
19) Niles N W, et al:Northern New England Cardiovascular Disease Study Group. Survival of patients with diabetes and multivessel coronary artery disease after surgical or percutaneous Coronary revascularization:results of a large regional prospective study. Northern New England Cardiovascular Disease Study Group. J Am Coll Cardiol 37 (4):1008-1015, 2001.
 
20) Pell J p, et al:Comparison of survival following coronary artery bypass grafting vs. percutaneous coronary intervention in diabetic and non-diabetic patients:retrospective cohort study of 6320 procedures. Diabet Med 21 (7):790-792, 2004.
PubMed
21) Katritsis D G, et al:Meta-analysis comparing drug-eluting stents with bare metal stents. Am J Cardiol 95:640-643, 2005.
PubMed
22) Flaherty J D, et al:Diabetes and coronary revascularization. JAMA 293 (12):1501-1508, 2005.
PubMed
23) Sobel B E, et al:Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial. Burgeoning dilemmas in the management of diabetes and cardiovascular disease:rationale fbr the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Circulation 107 (4):636-642, 2003.
 
P.195 掲載の参考文献
1) Armstrong D G, et al:Validation of a diabetic wound classification system:the contribution of depth, infection and ischemia to risk of amputation. Diabetes care 21:855-859, 1988.
 
2) 新城孝道:糖尿病フットケアガイド-診断, 治療, ケアの指針 p106-126, 医歯薬出版, 東京, 2004.
 
3) Benjamin A, et al:Diagnosis and treatment of diabetic foot infection. CID 39 (1):885, 2004.
 
4) Frykberg R G, et al:Diabetic foot disorders:a clinical practice guideline. J Foot Ankle Surg 38 (suppl):1-60, 2000.
 
5) International consensus on the diabetic foot, International Working Group on the diabetic foot, 2003.
 
6) The Sanford guide to antimicrobial therapy 2004 (34th edition) (Gilbert D N, et al, eds), Antimicrobial Therapy Inc. USA, 2004.
 
7) Trebor J, et al:Assessment of peripheral vascular disease in diabetes. Report and recommendation of an international workshop sponsored by the american diabetes association and the american heart association. Circulation 88:819-828, 1993.
 
8) Management of peripheral arterial disease (PAD), TransAtlantic Inter-Society Consensus:Jof Vascular surgery (TACS), Supplement 31, 1999.
 
9) 牧野寛史, 他:遺伝子を利用した血管再生治療. Geriatric Medicine 41 (12):1759-1764, 2003.
Medical*Online
10) Wagner F W Jr:Orthopaedic rehabilitatiom of the dysvascular limb. Orthop Clin North Am 9:325-350, 1978.
 
11) Wurschert R, et al:Determination of amputation level in ischemic limbs. Diabetes care 20:1315-1318, 1997.
 

第4章 糖尿病合併症のガイドライン

P.203 掲載の参考文献
1) American Diabetes Association:Standards of medical care in diabetes. Diabetes Care 28 (1) suppl:4-36, 2005.
 
2) 科学的根拠に基づく糖尿病診療ガイドライン策定に関する委員会:科学的根拠に基づく糖尿病診療ガイドライン. 日本糖尿病学会編 南江堂, 東京, 2004.
 
3) The Diabetes Control and Complications Trial (DCCT) Research Group:The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (14):977-986, 1993.
 
4) Ohkubo Y, et al:Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus:A randomized prospective 6-year study. Diabetes Res Clin Pract 28 (2):103-117, 1995.
PubMed
5) United Kingdom Prospective Diabetes Study (UKPDS) Group:Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (9131):837-853, 1998.
 
6) United Kingdom Prospective Diabetes Study (UKPDS) Group:Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS38). BMJ 317 (7160):703-713, 1998.
 
7) Chaturvedi N, et al, the EUCLID Study Group:Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 351 (9095):28-31, 1998.
 
8) Baba S:Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract 54 (3):191-201, 2001.
PubMed
9) United Kingdom Prospective Diabetes Study (UKPDS) Group:Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 39). BMJ 317 (7160):713-720, 1998.
 
10) Bakris G L, et al:Preserving renal function in adults with hypertension and diabetes:A consensus approach. Am J Kidney Dis 36 (3):646-661, 2000.
PubMed
11) Lewis EJ, et al:Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (12):851-860, 2001.
PubMed
12) Brenner B M, et al:Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (12):861-869, 2001.
PubMed
13) Yokoyama H, et al:Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients. Diabetologia 40 (4):405-411, 1997.
PubMed
14) Chew E Y, et al:Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Arch Ophthalmol 113 (1):52-55, 1995.
PubMed
15) Diabetic Retinopathy Vitrectomy Study Research Group:Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Four-year results of a randomized trial:Diabetic Retinopathy Vitrectomy Study Report 5. Arch Ophthalmol 108 (7):958-964, 1990.
 
16) Lewis E J, et al:The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329 (20):1456-1462, 1993.
 
17) Parving H H, et al:The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 (12):870-878, 2001.
PubMed
18) 後藤由夫, 他:糖尿病性神経障害に対するエパルレスタット (ONO-2235) の臨床的研究. プラセボ (微量治験薬含有) を対照とした二重盲検群間比較試験. 医のあゆみ 152:405-416, 1990.
Medical*Online
P.211 掲載の参考文献
1) Kannel W B, et al:Diabetes and glucose tolerance as risk factors for cardiovascular disease:the Framingham study. Diabetes Care 2:120-126, 1979.
PubMed
2) Haffner S M, et al:Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234, 1998.
PubMed
3) Fox C S, et al:Trends in cardiovascular complications of diabetes. JAMA 292:2495-2499, 2004.
PubMed
4) Fujishima M, et al:Diabetes and cardiovascular disease in a prospective population survey in Japan:The Hisayama study. Diabetes 45 (Suppl 3):S14-16, 1996.
 
5) http://www.mhlw.go.jp/shingi/2003/08/s0806-4.html
 
6) 谷川高士, 他:ステント植え込み後の初期および遠隔期成績における糖尿病の影響. J Caridiol 39:133-140, 2002.
 
7) 日本糖尿病学会 糖尿病診療ガイドライン策定に関する委員会編:「科学的根拠 (evidence) に基づく糖尿病診療ガイドライン」糖尿病 45 (Suppl 1):2002.
 
8) 日本糖尿病学会 編:「科学的根拠に基づく糖尿病診療ガイドライン」 南江堂, 東京, 2004.
 
9) 野田光彦:科学的根拠 (evidence) に基づく糖尿病診療ガイドライン (2002). 別冊・医学のあゆみ「糖尿病.代謝症候群-state of arts 2004-2006」 (門脇孝, 他編):医のあゆみ 678-681, 2004.
 
10) Okubo K, et al:Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus:a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117, 1995.
 
11) 日本動脈硬化学会編:「動脈硬化性疾患診療ガイドライン」日本動脈硬化学会, 東京, 2002.
 

第5章 糖尿病合併症のトピックス

P.219 掲載の参考文献
1) The expert committee on the diagnosis and classification of diabetes mellitus:Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes care 20:1183-1197, 1997.
PubMed
2) The DECODE study group on behalf of the European Diabetes Epidemiology Group:Glucose tolerance and mortality:comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354:617-621, 1999.
 
3) DECODE study group:on behaif of the European Diabetes Epidemiology Group:Glucose tolerance and cardiovascular mortality:comparison of fasting and 2-hour diagnostic criteria Arch Intern Med 161:397-405, 2001.
 
4) Qiao Q, et al:Comparison of the fasting and 2-h glucose criteria for diabetes in different Asian cohorts. Diabetologia 43:1470-1475, 2000.
PubMed
5) DECODA Study Group:Cardiovascular risk profile assessment in Asian glucose intolerant individuals-an evaluation of the World Health Organization two-step strategy:The DECODA study. Diabetic Med 19:549-557, 2002.
 
6) Tominaga M, et al:Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose:the Funagata Diabetes Study. Diabetes Care 22:920-924, 1999.
 
7) Hanefeld M, et al:Post-challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intima-media thickness:the RIAD Study. Diabetic Medicine 17:835-840, 2000.
PubMed
8) Tofler G H, et al:Analysis of possible triggers of acute myocardial infarction (the MILIS study). Am J Cardiol 66 (1):22-27, 1990.
PubMed
9) 野出孝一:血管内皮機能. Mebio, 別冊 65-69, 2003.
 
10) Tuomilehto J, et al:Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350, 2001.
PubMed
11) Diabetes Prevention Program Research Group:Reduction in the incidence of type 2 diabetes with lifestyle intervention or met formin. N Engl J Med 346:393-403, 2002.
 
12) Chiasson J L, et al:Acarbose fbr prevention of type 2 diabetes mellitus:the STOP-NID-DM randomized trial. Lancet 359:2072-2077, 2002.
 
P.226 掲載の参考文献
1) Nishikawa T, et al:Evaluation of urinary 8-hydroxydeoxy-guanosine as a novel biomarker of macrovascular complications in type 2 diabetes. Diabetes Care 26(5):1507-1512, 2003.
PubMed
2) Hinokio Y, et al:Oxidative DNA damage in diabetes mellitus:its association with diabetic complications. Diabetologia 42 (8):995-998, 1999.
PubMed
3) Klann E, et al:A role for superoxide in protein kinase C activation and induction of long-term potentiation. J Biol Chem 273 (8):4516-4522, 1998.
PubMed
4) Venugopal S K, et al:Alpha-tocopherol decreases superoxide anion release in human monocytes under hyperglycemic conditions via inhibition of protein kinase C-alpha. Diabetes 51 (10):3049-3054, 2002.
PubMed
5) Inoguchi T, et al:High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD (P) Hoxidase in cultured vascular cells. Diabetes 49 (11):1939-1945, 2000.
 
6) Hunt J V, et al:Oxidative alterations in the experimental glycation model of diabetes mellitus are due to protein-glucose adduct oxidation. Some fundamental differences in proposed mechanisms of glucose oxidation and oxidant production. Biochem J 291 (Pt 2):529-535, 1993.
 
7) Ookawara T, et al:Site-specific and random fragmentation of Cu, Zn-superoxide dismutase by glycation reaction. Implication of reactive oxygen species. J Biol Chem 267 (26):18505-18510, 1992.
PubMed
8) Yan S D, et al:Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269 (13):9889-9897, 1994.
PubMed
9) Williamson J R, et al:Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 42(6):801-813, 1993.
PubMed
10) Nishikawa T, et al:Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404 (6779):787-790, 2000.
PubMed
11) Kiritoshi S, et al:Reactive oxygen species from mitochondria induce cyclooxygenase-2 gene expression in human mesangial cells:potential role in diabetic nephropathy. Diabetes 52 (10):2570-2577, 2003.
PubMed
12) Hammes H P, et al:Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 9 (3):294-299, 2003.
PubMed
13) Kakimoto M, et al:Accumulation of 8-hydroxy-2-deoxyguanosine and mitochondrial DNA deletion in kidney of diabetic rats. Diabetes 51 (5):1588-1595, 2002.
PubMed
14) Ziegler D, et al:Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia 38 (12):1425-1433, 1995.
PubMed
15) Ziegler D, et al:Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid:a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care 22 (8):1296-1301, 1999.
 
16) Ametov A S, et al:The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid:the SYDNEY trial. Diabetes Care 26 (3):770-776, 2003.
PubMed
17) Bursell S E, et al:High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes. Diabetes Care 22 (8):1245-1251, 1999.
PubMed
18) Lonn E, et al:Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes:results of the HOPE study and MICRO-HOPE sub-study. 2002. Diabetes Care 25 (11):1919-1927, 2002
 
P.238 掲載の参考文献
1) Shulman GI:Cellular mechanisms of insulin resistance. J Clin Invest 106:171-176, 2000,
PubMed
2) Shimomura I, et al:Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 401:73-76, 1999.
PubMed
3) Maeda K, et al:cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 221:286-296, 1996.
PubMed
4) Scherer P E, et al:A novel serum protein similar to Clq, produced exclusively in adipocytes. J Biol Chem 270:26746-26749, 1995.
 
5) Hu E, et al:AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271:10697-10703, 1996.
 
6) Nakano Y, et al:Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem (Tokyo) 120:802-812, 1996,
 
7) Mori Y, et al:Genome-wide search for type 2 diabetes in Japanese affected sibpairs confirms susceptibility genes on 3q, 15q, and 20q and identifies two new candidate Loci on 7p and llp. Diabetes 51 (4):1247-1255, 2002.
 
8) Hara K, et al:Genetic variation in the gene encoding adiponectin is associated with increased risk of type 2 diabetes in the Japanese population. Diabetes 51:536-540, 2002.
PubMed
9) Yamauchi T, et al:Inhibition of RXR and PPARγ ameliorates diet-inducedobesity and type 2 diabetes. J Clin Invest 108:1001-1013, 2001.
 
10) Yamauchi T, et al:The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946, 2001.
PubMed
11) Fruebis J, et al:Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 98:2005-2010, 2001.
PubMed
12) Berg A H, et al:The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7:947-953, 2001.
PubMed
13) Kubota N, et al:Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277:25863-25866, 2002.
PubMed
14) Maeda N, et al:Diet-induced insulin resistance in mice lacking adiponectin/ACRP30, Nat Med 8:731-737, 2002.
PubMed
15) Yamauchi T, et al:Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278:2461-2468, 2003.
PubMed
16) Yamauchi T, et al:Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288-1295, 2002.
PubMed
17) Tomas E, et al:Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain:acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA 99:16309-16313, 2002.
PubMed
18) Wu X, et al:Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes. Diabetes 52:1355-1363, 2003.
PubMed
19) Okamoto Y, et al:Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106:2767-2770, 2002.
PubMed
20) Yamauchi T, et al:Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762-769, 2003.
PubMed
21) Tsuchida A, et al:Insulin/Foxol pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem 279:30817-30822, 2004.
 
22) Narasimhan, et al:0smotin is a Homolog of Human Adiponectin and Controls Apoptosis in Yeast Through a Homolog of Human Adiponectin Receptor. Molecular Cell 17:171-180, 2005.
 
P.246 掲載の参考文献
1) Krolewski A S, et al:Epidemiologic approach to the etiology of type 1 diabetes mellitus and its complications. N Engl J Med 317:1390-1398, 1987.
 
2) Imperatore G, et al:Sib-pair linkage analysis for susceptibility genes for microvascular complications among Pima Indians with type 2 diabetes. Diabetes 47:821-830, 1998.
PubMed
3) Moczulski D K, et al:Major susceptibility locus for nephropathy in type 1 diabetes on chromosome 3q. Diabetes 47:1164-1169, 1998.
PubMed
4) Vardarli I, et al:Gene for susceptibility to diabetic nephropathy in type 2 diabetes maps to 18q22. 3-23. Kidney Int 62:2176-2183, 2002.
PubMed
5) Haga H, et al:Gene-based SNP discovery as part of the Japanese Millennium Genome Project:identification of 190,562 genetic variations in the human genome. J Hum Genet 47:605-610, 2002.
PubMed
6) Ohnishi Y, et al:A high-throughput SNP typing system for genome-wide association studies. J Hum Genet 46:471-477, 2001.
PubMed
7) Ozaki K, et al:Functional SNPs in the lymphotoxin-a gene that are associated with susceptibility to myocardial infarction. Nat Genet 32:650-654, 2002.
 
8) Suzuki A, et al:Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 34:395-402, 2003.
PubMed
9) Kanazawa A, et al:Association of the Gene EncodingWingless-Type Mammary Tumor Virus Integration-Site Family Member 5B (WNT5B) with Type 2 Diabetes. Am J Hum Genet 75:832-843, 2004.
PubMed
10) Kizawa H, et al:An aspartic acid repeat polymorphism in asporin inhibits chondrogenesis and increases susceptibility to os-teoarthritis. Nat Genet 37:138-144, 2005.
 
11) Maeda S:Genome-wide search for susceptibility gene to diabetic nephropathy by gene-based SNP. Diabetes Res Clin Pract 66S:S45-S47, 2004.
 
12) Tanaka N, et al:Association of solute carrier family 12 (sodium/chloride) member 3 with diabetic nephropathy, identified by genome-wide analyses of single nucleotide polymorphisms Diabetes 52:2848-2853, 2003.
PubMed
13) Shimazaki A, et al:Genetic variations in the gene encoding engulfment and cell motility 1 (ELMO1) are associated with susceptibility to diabetic nephropathy. Diabetes 2005. (in press)
 
14) Ko BC, et al:An (A-C) n dinucleotide repeat polymorphic marker at the 5' end of the aldose reductase gene is associated with early-onset diabetic retinopathy in NIDDM patients. Diabetes 44:727-732, 995.
 
15) Awata T, et al:Acommon polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 51:1635-1639, 2002.
 
16) International Human Genome Sequencing Consortium:Finishing the euchromatic sequence of the human genome. Nature 31:931-945, 2004.
 
17) The International HapMap Consortium:The International HapMap Project. Nature 426:789-796, 2003.
 
P.254 掲載の参考文献
1) Moreno PR, MD et al:New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol 44:2293-2300, 2004.
 
2) Widlansky M E, et al:The clinical implications of endothelial dysfunction. J Am Coll Cardiol 42:1149-1160, 2003.
PubMed
3) Isner J M, et al:Arterial gene transfer for therapeutic angiogenesis in patients with peripheral artery disease. Hum Gene Ther 7:959-988, 1996.
PubMed
4) Isner J M, et al:Assessment of risks associated with cardiovascular gene therapy in human subjects. Circ Res 89:389-400, 2001.
PubMed
5) Asahar T, et al:Isolation of putative progenitor endothelial cells fbr angiogenesis. Science 275:964-967, 1997.
 
6) Tateishi-Yuyama E, et al:for the Therapeutic Angiogenesis using Cell Transplantation (TACT) Study Investigators. Therapeutic angiogenesis for patients with limbischemia by autologous transplantation of bone-marrow cells:a pilot study and a randomized controlled trial. Lancet 360:427-435, 2002.
 

書評

最近チェックした商品履歴

Loading...